Mapping geographic variability of severe uncontrolled asthma in the United States

Abstract

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Out-of-Pocket Costs and Prescription Filling Behavior of Commercially Insured Individuals With Chronic Obstructive Pulmonary Disease

“…This cohort study used IQVIA Longitudinal Access and Adjudication Data [2][3][4] for claims limited to patients filling COPD prescriptions between July 2017 and December 2019 through commercial insurance. Patient benefit design assignments were based on the highest cost-benefit design observed for all filled claims for that patient (COPD and non-COPD) in a calendar year, exclusive of any supplementary payment (eg, manufacturer copayment cards).…”

Systemic corticosteroids in asthma: A call to action from World Allergy Organization and Respiratory Effectiveness Group

“…Although SCS use has not historically been closely monitored in the past, geographic mapping of severe uncontrolled asthma across the USA has been recently completed in order to assess CS usage to guide therapies and improve outcomes in patients with severe asthma. 20 After adjusting for variables such as cities with the greatest disease burden, some counties (smaller regions within states) were found to have higher rates of SCS prescriptions and rates of asthma-related mortality than others, highlighting the need for monitoring of SCS prescriptions so that SCS Stewardship strategies and education can be implemented in the areas with the highest need. 20 …”

“… 20 After adjusting for variables such as cities with the greatest disease burden, some counties (smaller regions within states) were found to have higher rates of SCS prescriptions and rates of asthma-related mortality than others, highlighting the need for monitoring of SCS prescriptions so that SCS Stewardship strategies and education can be implemented in the areas with the highest need. 20 …”

“… 19 Additionally, a US study of 640,936 individuals with severe asthma demonstrated that 22.5% filled ≥2 and 12.7% filled ≥3 SCS prescriptions annually. 20 Variation in the prevalence of SCS use globally and regionally may be attributed to multiple factors, including patient age, sex, disease severity, socioeconomic status, level of ICS use, and access to and reimbursement of alternative therapies. 3 , 16 , 17 , 21 Additional challenges are faced by children with asthma receiving SCS, who are at an increased risk of AEs compared with children with asthma not receiving SCS, yet the prevalence of SCS use in children with asthma remains high.…”

Are We Poised to Change the Trajectory of Maintenance Oral Corticosteroid Use in Severe Asthma in the Age of Biologics?

“…The prevalence of OCS-dependent asthma is still relatively high in various populations, and there is regional variability. 1 OCS toxicity is well-characterized, and there is evidence that relatively low levels of exposure can have significant negative consequences. 2 There has been a marked change in the therapeutic landscape for severe asthma with the approval of six biologics.…”